In Vitro
The computed 12-month bankruptcy probability of In Vitro is 0.2% (very low). The 2023 annual accounts show negative equity (€-236) and a net result of €-236. Its solvency ranks better than 15% of 505 sector peers (fiscal year 2023). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €-236 |
| Net result | €-236 |
| Better than sector | 15% |
| Active | 4 yrs |
Mixed profile: strong on stability, weaker on health.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | -5.8% | 45.6% | |
| Net result | €-236 | €7k | |
| Equity | €-236 | €22k | |
| Gross operating margin | €157 | €20k | |
| Total assets | €4k | €65k |
| Fiscal year | 2023 |
|---|---|
| Revenue | €18k |
| EBITDA | €96 |
| Net profit | €-236 |
| Cash flow | €14 |
| Staff costs | - |
| Income taxes | - |
| Dividends | - |
| Total assets | €4k |
| Equity | €-236 |
| Debt | €4k |
| of which ≤ 1y | €3k |
| of which > 1y | - |
| Working capital | €-828 |
| Employees (FTE) | - |
| 2023 | |
|---|---|
| Current ratio | 0.74 |
| Quick ratio | 0.74 |
| Working capital ratio | -20.5% |
| Solvency | -5.8% |
| Debt / equity | -18.14 |
| Long-term debt ratio | - |
| Interest coverage | 1.17 |
| Gross margin | 0.9% |
| Net margin | -1.3% |
| ROA | -5.8% |
| ROE | 100.0% |
| EBITDA margin | 0.5% |
| Days sales outstanding | 35d |
| Days payable outstanding | 25d |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2023 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €4k |
| Fixed assets | 21/28 | €2k |
| Tangible fixed assets | 22/27 | €2k |
| Current assets | 29/58 | €2k |
| Amounts receivable within one year | 40/41 | €2k |
| Cash & bank | 54/58 | €661 |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €4k |
| Equity | 10/15 | €-236 |
| Accumulated profits (losses) | 14 | €-236 |
| Amounts payable | 17/49 | €4k |
| Amounts payable within one year | 42/48 | €3k |
| Trade debts payable within one year | 44 | €1k |
| Income statement | ||
| Turnover | 70 | €18k |
| Gross operating margin | 9900 | €157 |
| Operating result | 9901 | €-154 |
| Financial charges | 65 | €82 |
| Result before taxes | 9903 | €-236 |
| Net result for the period | 9904 | €-236 |
| Result to be appropriated | 9905 | €-236 |
| NACE primary | 90391 |
| Legal form | Non-profit association(017) |
| Incorporation | 28-11-2021 |
| Status | Active |
| Postal code | 1000 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21812N1179/00A000 | Brussels | 242 m² | 1 · 212 m² | 20.0 m · 4 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
19-12-2022 Registered office moved within Brussel
- Rue Jorez 19a, 1070 Brussel → Rue Du Grand Hospice 23, 1000 Brussel
Technical details
{
"events": [
{
"kind": "zetel_clause_amendment_no_move",
"seat_type": "siege_social",
"new_address": {
"raw": "Rue Du Grand Hospice 23, 1000 Brussel",
"city": "Brussel",
"region": "brussels_hoofdstedelijk_gewest",
"street": "Du Grand Hospice",
"country": "BE",
"postcode": "1000",
"box_number": null,
"street_number": "23",
"locality_suffix": null
},
"old_address": {
"raw": "Rue Jorez 19a, 1070 Brussel",
"city": "Brussel",
"region": "brussels_hoofdstedelijk_gewest",
"street": "Jorez",
"country": "BE",
"postcode": "1070",
"box_number": null,
"street_number": "19a",
"locality_suffix": null
},
"effective_date": null,
"evidence_quote": "",
"region_changed": false,
"is_statute_change": true,
"nationality_change": false,
"old_address_source": "header_volledig_adres",
"statute_clause_text": null,
"statute_article_number": null,
"effective_date_qualifier": "not_specified",
"statutaire_vs_werkelijke": "statutaire",
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2022-12-19",
"filing_date": "2022-12-09",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "algemene_vergadering",
"date": "2022-11-11",
"unanimous": null
},
"subject_company": {
"kbo": "0777.781.533",
"name_full": "In vitro",
"legal_form": "VZW",
"_kbo_filled_from_list": true
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Sibylle Tilliard",
"org_rep_person_name": null,
"person_role_at_subject": "bestuurder"
},
"co_filed_documents": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | In Vitro |
| AbbreviationNL | IV |